Please ensure Javascript is enabled for purposes of website accessibility

Natus Medical Continues Its Restructuring

By Brian Orelli, PhD - Apr 29, 2019 at 12:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's a rebuilding year for the medical device maker.

Natus Medical (NTUS 0.73%) continued its restructuring, which resulted in an ugly first quarter. Fortunately, with expectations low, investors were able to shrug it off in hopes that the medical device maker will be able to come out the other side a better company.

Natus Medical results: The raw numbers


Q1 2019

Q1 2018

Year-Over-Year Change


$114.8 million

$128.6 million


Income from operations

($24.2 million)

($2.7 million)


Earnings per share (EPS)




Adjusted EPS




Data source: Natus Medical.

What happened with Natus Medical this quarter?

  • The revenue decline was mostly driven by the previously announced exit of its NeuroCom Balance product line, and the ambulatory EEG video service called Global Neurodiagnostics (GND).
  • Lower revenue from the Medix business in Argentina also contributed to the decline. Earlier this month, after the close of the quarter, Natus announced plans to sell the low-margin Medix business to the subsidiary's employees.
  • There was also a year-over-year decline in sales of audiology products that were on hold pending product registrations, but most of those registrations were completed near the end of the first quarter, so their impact should wane in the quarters ahead.
  • Helping to balance out the declines, sales of EEG products increased 12.5% year over year.
  • The GAAP loss was almost entirely due to nearly $24 million in restructuring expenses -- $19 million for the divestiture of Medix and $4.6 million of severance in other parts of the company. Intangible amortization and other adjustments brought the adjusted EPS into the black.
A technician helps a woman with her hearing aid

Image source: Getty Images.

What management had to say

Natus' president and CEO Jonathan Kennedy highlighted the $4 million that the company plans to save this year as part of the restructuring, which it's dubbed One Natus: "I'm happy to report that we are on track to achieve these savings, and continue to expect additional ongoing annual benefits beyond 2019 that will enable us to achieve our immediate target model of ... 15% to 17% non-GAAP operating margin."

Kennedy also hinted that the cuts might not be done:

So a big part of One Natus is: This is a portfolio review, and trying to identify businesses that are not profitable and take up our time for no reward. And so you've seen us do that with the Medix business now, you've seen us do that with GND. We continue to look at the portfolio for other business that meets that criteria.

Looking forward

Management lowered 2019 guidance slightly: Revenue is now expected to come in between $489 million and $505 million, down from previous guidance of $490 million to $510 million. Adjusted earnings guidance was tightened to between $1.17 and $1.44 per share from previous guidance of $1.12 to $1.49 per share, although the new range is still pretty wide, and could signal the company's turnaround may take a while.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Natus Medical Incorporated Stock Quote
Natus Medical Incorporated
$32.91 (0.73%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.